Skip to main content
. 2022 Mar 7;13:806737. doi: 10.3389/fphar.2022.806737

FIGURE 5.

FIGURE 5

HER2-targeted TKIs pyrotinib, afatinib, dacomitinib, and poziotinib (A) were performed in cellular kinase inhibition assay to inhibit HER2 wild type (B) and A775_G776insYVMA (C) Ba/F3 cells. IC50 values of above four inhibitors against HER2 wild type and A775_G776insYVMA cells (D).